Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome

Simple item page
dc.contributor.authorGüçlü F.
dc.contributor.authorÖzmen B.
dc.contributor.authorHekimsoy Z.
dc.contributor.authorKirmaz C.
dc.date.accessioned2024-07-22T08:24:30Z
dc.date.available2024-07-22T08:24:30Z
dc.date.issued2004
dc.description.abstractBackground. - In West of Scotland Coronary Prevention Study (WOSCOPS), development of type 2 diabetes mellitus (DM) was found to decrease by 30% in pravastatin-treated patients. In the study, it is suggested that pleiotropic effects of pravastatin may be responsible too as well as its lipid lowering effect. Objective. - The aim of this study was to assess the effects of pravastatin treatment on the insulin resistance in patients with metabolic syndrome with impaired glucose tolerance (IGT), by Homeostasis Model Assessment (HOMA) test, insulin sensitivity indices and glucose half activation time (glucose t1/2). Methods. - Study population consisted of 25 women who were diagnosed with metabolic syndrome. At baseline and 10 weeks after the 20 mg/daily tablet pravastatin treatment, waist/hip circumference, body weight and arterial blood pressure measurements, plasma glucose, total cholesterol, triglyceride, high density lipoprotein (HDL)-cholesterol, transaminases, glycosylated haemoglobin (A1C) and insulin level measurements were obtained along with HOMA test and insulin tolerance test after 12 h of fasting. Insulin sensitivity indices and glucose t1/2 were assessed. Results. - After the treatment, a statistically significant decrease was observed in arterial blood pressure values (P < 0.0001). While plasma total cholesterol, low density lipoprotein (LDL)-cholesterol, and triglyceride levels were found to decrease significantly and HDL-cholesterol levels increased significantly, a decrease in baseline insulin levels, an increase in insulin sensitivity levels were observed along with an decrease in glucose t1/2. Related to the improvement in aforementioned parameters, statistically significant decreases were noted in HOMA, postprandial and fasting glucose levels and A1C values (P < 0.0001). Conclusion. - Our study suggests that using pravastatin in the dyslipidemia treatment of metabolic syndrome with IGT may be an effective approach by its advantageous effects on insulin resistance. Based on this result, it is possible to say that this can be a risk lowering treatment approach for the development of type 2 DM. © 2004 Elsevier SAS. All rights reserved.
dc.identifier.DOI-ID10.1016/j.biopha.2004.09.005
dc.identifier.issn07533322
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/19999
dc.language.isoEnglish
dc.publisherElsevier Masson SAS
dc.subjectaminotransferase
dc.subjectcholesterol
dc.subjectglucose
dc.subjectglycosylated hemoglobin
dc.subjecthigh density lipoprotein cholesterol
dc.subjecthydroxymethylglutaryl coenzyme A reductase inhibitor
dc.subjectinsulin
dc.subjectpravastatin
dc.subjecttriacylglycerol
dc.subjectadult
dc.subjectaminotransferase blood level
dc.subjectarterial pressure
dc.subjectarticle
dc.subjectblood pressure measurement
dc.subjectbody weight
dc.subjectcholesterol blood level
dc.subjectclinical article
dc.subjectcontrolled study
dc.subjectdrug effect
dc.subjectfemale
dc.subjectglucose blood level
dc.subjectglucose homeostasis
dc.subjecthuman
dc.subjectimpaired glucose tolerance
dc.subjectinsulin blood level
dc.subjectinsulin resistance
dc.subjectinsulin sensitivity
dc.subjectinsulin tolerance test
dc.subjectmetabolic syndrome X
dc.subjectpostprandial state
dc.subjectpriority journal
dc.subjectstatistical significance
dc.subjecttriacylglycerol blood level
dc.subjectwaist circumference
dc.titleEffects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome
dc.typeArticle

Files

Collections

Scopus Koleksiyonu